Group 1 - The core announcement is regarding the convening of the 2025 Second Extraordinary General Meeting of Shareholders by Jilin Aodong Pharmaceutical Group Co., Ltd. [2][3] - The meeting will adopt a combination of on-site voting and online voting methods to facilitate shareholder participation [3][5] - The meeting is legally compliant and has been approved by the company's board of directors [3] Group 2 - The meeting is scheduled for November 24, 2025, with specific times for on-site and online voting [4] - The record date for shareholders to attend the meeting is November 17, 2025 [6] - Eligible attendees include ordinary shareholders, company directors, senior management, and appointed lawyers [6][7][8] Group 3 - The agenda includes proposals that have been approved by the board, specifically regarding the appointment of independent directors [11] - Proposals require a simple majority for approval, with separate counting for small investors' votes [12] - The meeting will be held at the company's office in Dunhua City, Jilin Province [10] Group 4 - Shareholders must register to attend the meeting, with specific registration procedures outlined for both corporate and individual shareholders [13] - Registration will be open from November 20, 2025, during specified hours [14] - Contact information for the company is provided for further inquiries [15] Group 5 - Detailed procedures for participating in online voting are included, with specific timeframes and requirements for identity verification [17][20] - The voting process allows shareholders to express their opinions on proposals, with guidelines for how to cast votes [18][19] - An authorization letter template is provided for shareholders who wish to delegate their voting rights [21]

证券代码：000623 证券简称：吉林敖东 公告编号：2025-064 吉林敖东药业集团股份有限公司 关于召开 2025 年第二次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要提示： 1.吉林敖东药业集团股份有限公司已于 2025 年 11 月 7 日发布《关于召开 2025 年第二 次临时股东会的通知》（公告编号：2025-061），为进一步保护投资者的合法权益，方便股 东行使股东会表决权，现发布《关于召开 2025 年第二次临时股东会的提示性公告》。 2.本次股东会采取现场投票与网络投票相结合的方式。 吉林敖东药业集团股份有限公司（以下简称"公司"）第十一届董事会第二十次会议决 议召开公司 2025 年第二次临时股东会（以下简称"本次股东会"），本次股东会采用现场 投票和网络投票相结合的表决方式，现将有关事项通知如下： 一、召开会议的基本情况 1、股东会届次：2025 年第二次临时股东会 2、股东会的召集人：董事会 3、会议召开的合法、合规性：经公司第十一届董事会第二十次会议审议通过，决定召 开公司 2025 年第二次临时股东 ...

Core Viewpoint - Jilin Aodong's stock price has experienced fluctuations, with a recent decline of 2.01%, while the company shows a significant increase in net profit year-on-year despite a decrease in revenue [1][2]. Group 1: Stock Performance - As of November 17, Jilin Aodong's stock price is 20.49 CNY per share, with a market capitalization of 24.504 billion CNY [1]. - The stock has increased by 22.11% year-to-date, but has decreased by 4.61% over the last five trading days [1]. - The trading volume on November 17 was 1.01 billion CNY, with a turnover rate of 0.41% [1]. Group 2: Financial Performance - For the period from January to September 2025, Jilin Aodong reported revenue of 1.640 billion CNY, a year-on-year decrease of 14.10% [2]. - The net profit attributable to shareholders for the same period was 2.260 billion CNY, reflecting a year-on-year increase of 81.70% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders is 61,200, a decrease of 7.18% from the previous period [2]. - The average number of circulating shares per shareholder is 19,456, which has increased by 7.73% [2]. - The company has distributed a total of 4.664 billion CNY in dividends since its A-share listing, with 1.881 billion CNY distributed in the last three years [3].

Group 1 - The core viewpoint indicates a strong performance in the Traditional Chinese Medicine (TCM) sector, with the Zhongzheng TCM Index rising by 1.22% and individual stocks like Zhongsheng Pharmaceutical increasing by 9.98% [1] - The TCM ETF has shown a consistent upward trend, achieving an 8-day consecutive rise, with the latest price reported at 1.06 yuan [1] - The National Health Commission has projected a peak in influenza cases in China during mid-December to early January, which may positively impact the TCM market [1] Group 2 - CITIC Securities anticipates that the collection of traditional Chinese medicine will continue to expand, leading to increased brand concentration in the outpatient market [1] - The TCM industry is expected to reach a healthy inventory level by Q2 2025, following a period of destocking and sales efforts [1] - Continuous growth in R&D investment by TCM companies is highlighted as a key driver for future development, with a focus on innovative TCM contributing to stable growth [1]

证券代码：000623 证券简称：吉林敖东 公告编号:2025-063 吉林敖东药业集团股份有限公司 关于公开发行可转换公司债券部分募集资金专户销户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会《关于核准吉林敖东药业集团股份有限公司公开 发行可转换公司债券的批复》（证监许可[2018]184 号）核准，吉林敖东药业集 团股份有限公司（以下简称"公司"）于 2018 年 3 月 13 日公开发行了面值总额 241,300 万元的可转换公司债券，扣除发行费用 2,446.13 万元后，募集资金净 额为 238,853.87 万元。截至 2018 年 3 月 19 日，上述募集资金已经到位。中准 会计师事务所（特殊普通合伙）已对上述募集资金到位情况出具了验资报告。 二、募集资金存放和管理情况 （一）募集资金管理情况 为了规范募集资金的管理和使用，保护投资者权益，本公司修订了《募集资 金管理办法》。该管理办法经公司第九届董事会第二次会议、第九届监事会第二 次会议、2017 年第二次临时股东大会决议通过；经公司第十 ...

Core Viewpoint - The Chinese traditional medicine sector, particularly the Chinese Medicine ETF (560080), is experiencing increased investor interest due to favorable market conditions and relatively low valuations, with a notable inflow of funds and positive performance in recent trading sessions [1][3][10]. Group 1: Market Performance - On November 10, the Shanghai Composite Index rose by 0.53%, with the consumer sector leading gains, particularly the Chinese medicine segment, which saw the Chinese Medicine ETF (560080) increase by 1.55% and a trading volume exceeding 160 million yuan [1]. - The Chinese Medicine ETF (560080) has seen a cumulative net inflow of over 260 million yuan in the past 20 days, bringing its total fund size to over 2.8 billion yuan, leading its peers significantly [1][3]. Group 2: Valuation Insights - As of November 7, the TTM price-to-earnings (PE) ratio of the Chinese Medicine ETF (560080) was 25.31, placing it at the 24.5% percentile over the past decade, indicating that the index is cheaper than 75% of the time historically [3]. - The TTM PE ratio is just 0.57 away from the calculated opportunity value, suggesting a higher cost-performance ratio for potential investors [3]. Group 3: Stock Performance - Most constituent stocks of the Chinese Medicine ETF (560080) showed positive performance, with notable gains from Yunnan Baiyao, Pianzaihuang, and Yiling Pharmaceutical, all rising over 2%, while others like Tongrentang and Dong'e Ejiao also saw increases [5][6]. Group 4: Industry Trends - The Chinese medicine index has shown negative returns year-to-date, with a decline of 0.24% this year and an 8.13% drop in 2024, indicating a challenging market environment [7]. - Despite recent struggles, analysts suggest that the sector may be approaching a turning point, with potential improvements in performance expected due to rising flu incidence and better management of inventory levels among leading OTC Chinese medicine companies [10][11]. Group 5: Institutional Insights - Analysts from Zheshang Securities highlight that the Chinese medicine industry has characteristics similar to the banking sector, with strong cash flow and stable profit growth, suggesting resilience against external shocks [11]. - The industry is expected to see improved revenue growth in the second half of 2025, driven by declining raw material prices and cost-cutting measures by companies [11].

Core Viewpoint - Jilin Aodong's stock price has shown a significant increase this year, with a notable rise in net profit despite a decrease in revenue, indicating potential resilience in its business model and market positioning [1][2]. Financial Performance - As of September 30, 2025, Jilin Aodong reported a revenue of 1.64 billion yuan, a year-on-year decrease of 14.10%, while the net profit attributable to shareholders was 2.26 billion yuan, reflecting a year-on-year increase of 81.70% [2]. - The company's stock price increased by 28.67% year-to-date, with a 0.84% rise over the last five trading days, 6.18% over the last 20 days, and 13.91% over the last 60 days [1]. Shareholder Information - The number of shareholders decreased by 7.18% to 61,200, while the average circulating shares per person increased by 7.73% to 19,456 shares [2]. - The company has distributed a total of 4.664 billion yuan in dividends since its A-share listing, with 1.881 billion yuan distributed in the last three years [3]. Ownership Structure - As of September 30, 2025, the top ten circulating shareholders included Southern CSI 500 ETF, holding 13.93 million shares (a decrease of 317,900 shares), and Hong Kong Central Clearing Limited, holding 11.82 million shares (a decrease of 319,620 shares) [3].

Core Insights - The Chinese medicine market is experiencing rapid growth, driven by favorable policies and increasing market demand, as highlighted by the recent 12th World Traditional Chinese Medicine Conference held in Sydney, Australia [1][2]. Group 1: Market Performance - As of November 10, 2025, the Zhongzheng Traditional Chinese Medicine Index (930641) rose by 1.11%, with notable increases in stocks such as Zhongsheng Pharmaceutical (002317) up 3.69% and Kangyuan Pharmaceutical (600557) up 3.22% [1]. - The Traditional Chinese Medicine ETF (159647) increased by 0.88%, with the latest price reported at 1.03 yuan [1]. Group 2: Industry Growth Drivers - The conference attracted over 800 representatives from 24 countries, emphasizing the global interest in the dissemination and technological innovation of traditional Chinese medicine [1]. - Pacific Securities notes that the industry is supported by comprehensive measures across supply, payment, and demand sides, including registration, review, quality control, and cultural promotion [1]. Group 3: Key Constituents - As of October 31, 2025, the top ten weighted stocks in the Zhongzheng Traditional Chinese Medicine Index accounted for 54.92% of the index, including major players like Yunnan Baiyao (000538) and Tongrentang (600085) [2].

Group 1 - The company held its 20th meeting of the 11th Board of Directors on November 6, 2025, with all 9 directors present, including independent directors attending via remote voting [1][3][4] - The meeting approved the proposal regarding the resignation and re-election of an independent director, with a unanimous vote of 9 in favor [3][5] - The company plans to hold its second extraordinary general meeting of shareholders on November 24, 2025, at 14:00 [4][5] Group 2 - The independent director Liang Biming submitted his resignation on November 5, 2025, due to personal reasons, and will continue to fulfill his duties until a new independent director is elected [77][78] - Zhang Chunying has been nominated as the candidate for the independent director position, recommended by the largest shareholder, Dunhua Jincheng Industrial Co., Ltd., which holds 27.35% of the company's shares [78][79] - The independent director candidate must pass the qualification and independence review by the Shenzhen Stock Exchange before the shareholders' meeting can vote on the proposal [79] Group 3 - The company ensures that the notice for the extraordinary general meeting complies with relevant laws and regulations, including the Company Law and the Shenzhen Stock Exchange rules [83] - The meeting will adopt a combination of on-site and online voting methods, with specific voting times outlined [84][86] - Shareholders must register to attend the meeting, with detailed registration procedures provided [93][94]

Core Viewpoint - Jilin Aodong has announced the nomination of Ms. Zhang Chunying as an independent director candidate for the company's 11th Board of Directors [2] Company Summary - Jilin Aodong has made a formal announcement regarding the nomination of a new independent director [2]